52 completed, 12 terminated, 10 recruiting, 8 active not recruiting. 88 Phase 2, 23 Phase 1, 2 Phase 3.
Follow Thrombocythemia, Essential: new trials by email Literature Review of Thrombocythemia, Essential trials Research Report on Thrombocythemia, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-11-16 |
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial STP938 - Essential Thrombocythaemia | Phase 2 | Recruiting | Step Pharma, SAS | 50 | 2025-06-18 | 2026-06-16 |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Phase 1 / Phase 2 | Recruiting | Jubilant Therapeutics Inc. | 30 | 2024-10-21 | 2026-06-03 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Peginterferon α-2b injection - Essential Thrombocythemia | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 27 | 2024-08-29 | 2025-11-17 |
| Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia | Phase 2 | Recruiting | University of Southern California | 30 | 2024-03-01 | 2026-03-27 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera Ruxolitinib - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2022-03-21 | 2026-01-08 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms N-Acetylcysteine - Myeloproliferative Neoplasm, MPN | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 27 | 2022-01-03 | 2026-03-10 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) IMG-7289 - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Active not recruiting | Terrence J Bradley, MD | 4 | 2020-10-02 | 2026-01-07 |
| Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) Bomedemstat - Essential Thrombocythemia | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 73 | 2020-09-08 | 2026-05-04 |
| Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 IMG-7289 - Thrombocythemia, Essential | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 9 | 2020-04-09 | 2026-10-22 |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Recruiting | University of Washington | 25 | 2020-03-24 | 2026-09-17 |
| Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia Recombinant Interferon Alpha, Pegylated interferon alfa-2b - Essential Thrombocytopenia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2020-01-10 | 2024-07-03 |
| Dual Vaccine Trial in Myeloproliferative Neoplasms PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia | Phase 1 / Phase 2 | Completed | Inge Marie Svane | 9 | 2019-07-10 | 2023-07-13 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
Showing 20 of 88. Sign in to see all of them.
Polycythemia Vera (73) · Primary Myelofibrosis (64) · Myeloproliferative Disorders (56) · Leukemia, Myeloid, Acute (31) · Leukemia, Myelomonocytic, Chronic (30) · Myelodysplastic Syndromes (29) · Leukemia (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Multiple Myeloma (22) · Leukemia, Myeloid, Accelerated Phase (21) · Lymphoma, Non-Hodgkin (21) · Blast Crisis (20) · Congenital Abnormalities (20)
Hemic and Lymphatic Diseases (88) · Blood Coagulation Disorders (86) · Blood Platelet Disorders (86) · Hemorrhagic Disorders (86) · Bone Marrow Diseases (84) · Thrombocytosis (83) · Hematologic Diseases (82) · Neoplasms by Site (75) · Bone Marrow Neoplasms (73) · Hematologic Neoplasms (73) · Neoplasms (73) · Neoplasms by Histologic Type (41) · Leukemia, Myeloid (40) · Chronic Disease (39) · Disease Attributes (39)
fludarabine phosphate (19) · Cyclophosphamide (18) · Peripheral Blood Stem Cell Transplantation (16) · Busulfan (14) · Whole-Body Irradiation (11) · Cyclosporine (10) · Methotrexate (10) · Mycophenolic Acid (10) · Tacrolimus (10) · ruxolitinib (8) · Antilymphocyte Serum (7) · fludarabine (6) · Radiotherapy (5) · Biopsy (4) · bomedemstat (4)
Fred Hutchinson Cancer Center (11) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (5) · Mayo Clinic (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Italfarmaco (3) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (2) · OHSU Knight Cancer Institute (2) · Ronald Hoffman (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Sierra Oncology LLC - a GSK company (2) · Asan Medical Center (1) · Baylor College of Medicine (1) · Cancer Treatment Centers of America (1) · Case Comprehensive Cancer Center (1)
United States (66) · Germany (11) · Italy (10) · United Kingdom (10) · France (9) · Australia (7) · Canada (6) · Belgium (3) · Denmark (3) · Netherlands (3) · Switzerland (3) · China (2) · Hong Kong (2) · New Zealand (2) · Poland (2)
Ruben A. Mesa, MD (4) · Alessandro Rambaldi, MD (3) · H. Joachim Deeg, MD (2) · Jorge Cortes, MD (2) · Teresa Field, MD, PhD (2) · Uday Popat, MD (2) · Usama Gergis, MD (2) · Albert Assad, MD (1) · Amy E DeZern, MD (1) · Anand A Patel (1) · Andrew Roberts, M.D. (1) · Angela Fleischman, MD, PhD (1) · Ann E. Woolfrey, MD (1)
PMID 32499241, PMID 11468154, PMID 19841031, PMID 20651074, PMID 22943924, PMID 24362550, PMID 24903629, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26332546, PMID 27479177, PMID 28291640, PMID 28622623, PMID 29152412, PMID 30409796, PMID 30630975, PMID 32634234, PMID 32732354, PMID 33609248, PMID 36564535, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 37592092, PMID 38259250, PMID 40330782, PMID 40775758, PMID 41758981, PMID 42306077, PMID 9326205
P30CA015083 (4), P01CA015396 (2), P01CA018029 (2), P01CA108671 (2), P30CA006973 (2), P30CA015704 (2), 2004 (1), 2018 (1), 2019 (1), N01CM17104 (1), N01CM62201 (1), P01CA078902 (1), P30CA014089 (1), P30CA014599 (1), P30CA016058 (1)